ArriVent to present initial Phase 1 data for ARR-217 in gastrointestinal cancers at ESMO 2026
AVBP•ArriVent Biopharma will present initial Phase 1 safety and efficacy data for ARR-217 in gastrointestinal cancers at ESMO on October 25, 2026.
1. Planned data presentation
ArriVent Biopharma will present initial Phase 1 safety and efficacy data for ARR-217 in gastrointestinal cancers at ESMO on October 25, 2026. The first-in-human study evaluates the CDH17-targeted antibody-drug conjugate, also known as MRG007, in patients with locally advanced or metastatic solid tumors.
2. Webinar scheduled
A virtual webinar to discuss the data and development program is scheduled for October 26, 2026, at 8 a.m. ET.
